Ken Griffin Verona Pharma PLC Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 93,200 shares of VRNA stock, worth $7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,200
Previous 70,600
32.01%
Holding current value
$7 Million
Previous $3.28 Million
80.51%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$493 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$414 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$294 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$260 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$217 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.58B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...